The drug was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the disease.
By Deena Beasley and Julie Steenhuysen (Reuters) - In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administrati.
By Deena Beasley and Julie Steenhuysen (Reuters) - In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administrati.
By Deena Beasley and Julie Steenhuysen (Reuters) - In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administrati.
By Deena Beasley and Julie Steenhuysen (Reuters) - In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administrati.